Design considerations and implications of findings on progressive pulmonary fibrosis from the prospective Canadian Registry for Pulmonary Fibrosis.

Competing Interests: Conflict of interest: C.J. Ryerson reports support for the present manuscript from Boehringer Ingelheim; grants from Boehringer Ingelheim and Hoffmann-La Roche; consulting fees from Boehringer Ingelheim, Hoffmann-La Roche, AstraZeneca, Veracyte, Ensho and Pliant Therapeutics; lecture honoraria from Boehringer Ingelheim, Hoffmann-La Roche and Cipla Ltd; travel support from Cipla Ltd and Boehringer Ingelheim; outside the submitted work. Conflict of interest: N. Hambly reports grants from Boehringer Ingelheim and Janssen; lecture honoraria and travel support from Boehringer Ingelheim, Janssen and Roche; outside the submitted work. Conflict of interest: M. Kolb reports support for the present manuscript from Boehringer Ingelheim; grants from Boehringer Ingelheim, Pieris and Roche; consulting fees from Boehringer Ingelheim, Roche, Horizon, Cipla, Abbvie, Bellerophon, Algernon, CSL Behring, United Therapeutics, LabCorp and ShouTi; lecture honoraria from Roche, Novartis, Boehringer Ingelheim; payment for expert testimony from Roche; advisory board participation from United Therapeutics and LabCorp; and reports an allowance as Chief Editor ERJ.